Vickers M R, Assem E S
Immunology. 1974 Feb;26(2):425-40.
The value of using benzylpenicilloyl (BPO) conjugates rather than benzylpenicillin (B.Pen.) itself in skin tests and in diagnostic tests for penicillin allergy in man is assessed. The effect of various carriers on the outcome of these tests has also been investigated in order to find the most appropriate. Skin tests with B.Pen. and BPO conjugates (with polylysine, PL, and human serum albumin, HSA) in penicillin allergic patients were positive in 36 per cent and up to 50 per cent respectively. The two carriers used were equally effective. Negative results were obtained in the non-allergic control subjects. For studies two tests were selected on the basis of their well established value, the lymphocyte transformation test (LTT) and histamine release from sensitized leucocytes (HRL). In the HRL test BPO conjugates with PL, HSA, bovine serum albumin (BSA) and bovine gamma globulin (BGG) were also compared with B.Pen. The BPO conjugates were all more effective than B.Pen. and the proportion of patients giving positive results with these conjugates was much higher than with B.Pen. (up to 86 per cent compared with 29 per cent). The rank order of effectiveness of the various carriers as judged from maximal histamine release by various penicilloyl conjugates was PL<BSA<HSA<BGG, BGG being the most effective. In the LTT, where BPO:PL, BPO:HSA, BPO:BGG as well as BPO human gamma globulin have been used, the BPO conjugates were also more effective than B.Pen. but the difference was relatively less marked than in HRL test (positive results being obtained with conjugates in up to 92 per cent of patients as compared with 57 per cent with B.Pen.). The rank order of effectiveness of the carriers in the LTT, as judged by comparing the maximum response obtained with each BPO-protein conjugate with the maximum response obtained with BPO:PL, was PL<HSA<HGG<BGG, BGG being the most effective. However, BPO:HGG was effective in lower concentrations. The HRL and LTT were negative in nine out of ten non-allergic subjects, and in control experiments with the carrier molecules alone.
评估了在人体皮肤试验和青霉素过敏诊断试验中使用苄青霉素酰(BPO)偶联物而非苄青霉素(B.Pen.)本身的价值。还研究了各种载体对这些试验结果的影响,以找出最合适的载体。对青霉素过敏的患者进行B.Pen.和BPO偶联物(与聚赖氨酸、PL,以及人血清白蛋白、HSA)的皮肤试验,阳性率分别为36%和高达50%。所使用的两种载体效果相同。非过敏对照受试者的试验结果为阴性。对于研究,根据其已确立的价值选择了两项试验,即淋巴细胞转化试验(LTT)和致敏白细胞组胺释放试验(HRL)。在HRL试验中,还将与PL、HSA、牛血清白蛋白(BSA)和牛γ球蛋白(BGG)偶联的BPO与B.Pen.进行了比较。BPO偶联物都比B.Pen.更有效,使用这些偶联物获得阳性结果的患者比例远高于使用B.Pen.的患者(高达86%,而B.Pen.为29%)。根据各种青霉素酰偶联物的最大组胺释放量判断,各种载体的有效性排序为PL<BSA<HSA<BGG,BGG最有效。在LTT中,使用了BPO:PL、BPO:HSA、BPO:BGG以及BPO人γ球蛋白,BPO偶联物也比B.Pen.更有效,但差异相对不如HRL试验明显(使用偶联物的患者阳性率高达92%,而B.Pen.为57%)。通过比较每种BPO - 蛋白质偶联物获得的最大反应与BPO:PL获得的最大反应来判断,LTT中载体的有效性排序为PL<HSA<HGG<BGG,BGG最有效。然而,BPO:HGG在较低浓度下也有效。十名非过敏受试者中有九名的HRL和LTT结果为阴性,且单独使用载体分子的对照实验结果也为阴性。